Evidence map›Paper›PMID 41990546›Full record

ArticleTranslational oncology2026

Clinical usefulness of polygenic risk scores in risk prediction models for lung cancer screening and lung nodule management.

Véronique Boumtje, Zhonglin Li, Nathalie Gaudreault, Victoria Saavedra Armero, Dominique K Boudreau, Sophie Plante, Sabrina Biardel, Aida Eslami, Simon Martel, Sébastien Thériault and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Véronique BoumtjeInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec City, Canada.
Zhonglin LiInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec City, Canada.
Nathalie GaudreaultInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec City, Canada.
Victoria Saavedra ArmeroInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec City, Canada.
Dominique K BoudreauInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec City, Canada.
Sophie PlanteInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec City, Canada.
Sabrina BiardelInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec City, Canada.
Aida EslamiInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec City, Canada; Department of Social and Preventive Medicine, Université Laval, Quebec City, Canada.
Simon MartelInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec City, Canada.
Sébastien ThériaultInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec City, Canada.
Philippe JoubertInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec City, Canada.
Yohan BosséInstitut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec City, Canada; Department of Molecular Medicine, Université Laval, Quebec City, Canada. Electronic address: yohan.bosse@criucpq.ulaval.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLung cancer mortality decreases as a result of low-dose computed tomography (LDCT) screening, but suffers from low uptake and high false-positive rates. The impact of integrating genetic risk using a polygenic risk score (PRS) to optimize lung cancer screening remains underexplored.

methodsWe developed a genome-wide PRS and evaluated its performance in pre- and post-screening contexts. Screening eligibility was assessed using two UK Biobank (UKB) subsets: UKB

resultsIn UKB

conclusionPRS in lung cancer reveals context-dependent net benefit across studied populations. Although PRS adds limited value for determining screening eligibility, it may help reclassify borderline individuals and inform decisions regarding closer follow-up or invasive diagnostic procedures for high-risk screened groups.

Indexed as

Lung cancer screeningLung nodule managementPolygenic susceptibility to lung cancer

Identifiers

PMID41990546
PMCPMC13096907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.